Literature DB >> 16918970

Podocalyxin-like protein 1 expression in primary hepatic tumours and tumour-like lesions.

L C Heukamp1, H P Fischer, P Schirmacher, X Chen, K Breuhahn, C Nicolay, R Büttner, I Gütgemann.   

Abstract

AIMS: The differential diagnosis of benign hepatic lesions and well-differentiated hepatocellular carcinomas can be a challenge, especially in small biopsy specimens. Recently, novel proteins expressed by the neovasculature in hepatocellular carcinoma (HCC) have been identified. The aim of this study was to compare the expression of podocalyxin-like protein 1 (PODXL1), a CD34-related sialomucin, in HCC and benign liver tumours or tumour-like lesions. METHODS AND
RESULTS: Vascular marker expression was examined using tissue microarrays as well as standard paraffin sections from formalin fixed paraffin-embedded liver tissue samples. Expression of PODXL1 was compared with anti-CD34, CD31 and von Willebrand factor VIII staining by immunohistochemistry. PODXL1 is expressed in tumour-associated microvasculature endothelial cells in HCC, as well as in capillarized sinusoidal endothelium of focal nodular hyperplasia (FNH) and hepatic adenoma. Expression in cirrhotic nodules correlates with CD34 and highlights endothelium in the inflow area. In dysplastic nodules CD34 and PODXL1 are not or only focally expressed.
CONCLUSIONS: Expression patterns of CD34 and PODXL1 are almost identical in primary hepatic tumours and tumour-like lesions. The presence of CD34+ and PODXL1+ sinusoidal endothelial cells aids in the diagnosis of HCC. Sinusoidal expression of PODXL1 is also seen in a less diffuse pattern in FNH and adenoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16918970     DOI: 10.1111/j.1365-2559.2006.02489.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  10 in total

1.  Podocalyxin EBP50 ezrin molecular complex enhances the metastatic potential of renal cell carcinoma through recruiting Rac1 guanine nucleotide exchange factor ARHGEF7.

Authors:  Yung-Ho Hsu; Wei-Ling Lin; Yi-Ting Hou; Yeong-Shiau Pu; Chia-Tung Shun; Chi-Ling Chen; Yih-Yiing Wu; Jen-Yau Chen; Tso-Hsiao Chen; Tzuu-Shuh Jou
Journal:  Am J Pathol       Date:  2010-04-15       Impact factor: 4.307

2.  Ubiquitous yet distinct expression of podocalyxin on vascular surfaces in normal and tumor tissues in the rat.

Authors:  Jacqueline E Testa; Adrian Chrastina; Yan Li; Phil Oh; Jan E Schnitzer
Journal:  J Vasc Res       Date:  2009-01-10       Impact factor: 1.934

3.  Diagnostic value of immunohistochemical staining of GP73, GPC3, DCP, CD34, CD31, and reticulin staining in hepatocellular carcinoma.

Authors:  Shuzhe Yao; Jianping Zhang; Haiyan Chen; Yan Sheng; Xiaoying Zhang; Zhiyan Liu; Cuijuan Zhang
Journal:  J Histochem Cytochem       Date:  2013-05-16       Impact factor: 2.479

4.  The Universal 3D3 Antibody of Human PODXL Is Pluripotent Cytotoxic, and Identifies a Residual Population After Extended Differentiation of Pluripotent Stem Cells.

Authors:  Lei Kang; Chunping Yao; Alireza Khodadadi-Jamayran; Weihua Xu; Ruowen Zhang; Nilam Sanjib Banerjee; Chia-Wei Chang; Louise T Chow; Tim Townes; Kejin Hu
Journal:  Stem Cells Dev       Date:  2016-04-01       Impact factor: 3.272

5.  Podocalyxin-like protein is an E-/L-selectin ligand on colon carcinoma cells: comparative biochemical properties of selectin ligands in host and tumor cells.

Authors:  Susan N Thomas; Ronald L Schnaar; Konstantinos Konstantopoulos
Journal:  Am J Physiol Cell Physiol       Date:  2008-12-31       Impact factor: 4.249

6.  Epidermal growth factor receptor mutations in non-small cell lung cancer influence downstream Akt, MAPK and Stat3 signaling.

Authors:  Sebastian Zimmer; Philip Kahl; Theresa M Buhl; Susanne Steiner; Eva Wardelmann; Sabine Merkelbach-Bruse; Reinhard Buettner; Lukas C Heukamp
Journal:  J Cancer Res Clin Oncol       Date:  2008-11-11       Impact factor: 4.553

7.  Membranous expression of podocalyxin-like protein is an independent factor of poor prognosis in urothelial bladder cancer.

Authors:  K Boman; A H Larsson; U Segersten; E Kuteeva; H Johannesson; B Nodin; J Eberhard; M Uhlén; P-U Malmström; K Jirström
Journal:  Br J Cancer       Date:  2013-05-07       Impact factor: 7.640

8.  Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma.

Authors:  Kapo Saukkonen; Jaana Hagström; Harri Mustonen; Anne Juuti; Stig Nordling; Christian Fermér; Olle Nilsson; Hanna Seppänen; Caj Haglund
Journal:  PLoS One       Date:  2015-06-08       Impact factor: 3.240

9.  Podocalyxin-like protein is expressed in glioblastoma multiforme stem-like cells and is associated with poor outcome.

Authors:  Zev A Binder; I-Mei Siu; Charles G Eberhart; Colette Ap Rhys; Ren-Yuan Bai; Verena Staedtke; Hao Zhang; Nicolas R Smoll; Steven Piantadosi; Sara G Piccirillo; Francesco Dimeco; Jon D Weingart; Angelo Vescovi; Alessandro Olivi; Gregory J Riggins; Gary L Gallia
Journal:  PLoS One       Date:  2013-10-16       Impact factor: 3.240

10.  The cell surface mucin podocalyxin regulates collective breast tumor budding.

Authors:  Marcia L Graves; Jane A Cipollone; Pamela Austin; Erin M Bell; Julie S Nielsen; C Blake Gilks; Kelly M McNagny; Calvin D Roskelley
Journal:  Breast Cancer Res       Date:  2016-01-22       Impact factor: 6.466

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.